A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01531790|
Recruitment Status : Completed
First Posted : February 13, 2012
Last Update Posted : January 16, 2013
|Condition or disease||Intervention/treatment||Phase|
|Non-Small Cell Lung Cancer||Drug: Carboplatin Drug: Pemetrexed Drug: Endostar Drug: Centrum||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced NSCLC Patients|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Experimental: Endostar plus pemetrexed/carboplatin
21 days as one cycle, for a total of 4-6 cycles
d1, AUC 5, i.v.
d1, 500 mg/m2, i.v.
d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
- Dose Limiting Toxicity [ Time Frame: up to 21 days ]
- Objective Response Rate [ Time Frame: up to 6 cycles ]
- Disease Control Rate [ Time Frame: up to 6 cycles ]
- Progression-free Survival [ Time Frame: up to 2 years ]
- Overall Survival [ Time Frame: up to 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01531790
|Sun Yat-sen University Cancer Center|
|Guangzhou, Guangdong, China|
|Principal Investigator:||Li Zhang, MD||Sun Yat-sen University|